This news from heartwire reveals that the use of low-dose aspirin in the primary prevention of cardiovascular events in healthy individuals with asymptomatic atherosclerosis is currently not warranted, according to the lead researcher of a large "real-world" study presented today at the European Society of Cardiology (ESC) 2009 Congress.
Primary End-Point Results for Aspirin vs Placebo
| End point | Aspirin (n=1675), n (%) | Placebo (n=1675), n (%) |
| Fatal coronary event | 28 (1.7) | 18 (1.1) |
| Fatal stroke | 7 (0.4) | 12 (0.7) |
| Nonfatal coronary event | 62 (3.7) | 68 (4.1) |
| Nonfatal stroke | 37 (2.2) | 38 (2.3) |
| Coronary revascularization | 24 (1.4) | 20 (1.2) |
| Peripheral revascularization | 23 (1.4) | 20 (1.2) |
They were randomly allocated to 100-mg enteric coated aspirin daily or to placebo and followed for a mean of 8.2 years. The primary end point of the trial was the composite of an initial fatal or nonfatal coronary event, stroke, or revascularization. Secondary end points were all vascular events, which included a composite of initial fatal or nonfatal coronary event, stroke, or revascularization, angina, intermittent claudication, transient ischemic attack, and all-cause mortality.
0 comments
Post a Comment